In this clinical trial, pembrolizumab and vorinostat, which is a pan-HDAC inhibitor, were administrated to patients with R/M HNSCC and salivary gland cancer; in the HNSCC cohort, 32% patients showed PR and 20% showed stable disease (SD). Here, HDAC9 is linked to salivary gland cancer.